For graduates of the STEM disciplines, there may be no better career choice than the biopharmaceutical industry. That is one of the many lessons I have learned in the course of three decades working in life sciences.
As a science graduate, I didn’t pursue a career in the pharmaceutical sector. In fact it was the furthest thing from my mind. I knew very little about the industry and, if I’m honest, the prospect of joining it did not particularly excite me. Had it not been for a stroke of serendipity, my career would almost certainly have taken a different path.
Thirty years later, I consider myself incredibly fortunate to have fallen into an industry that continues to advance human health so rapidly and profoundly. I work in an industry in which career opportunities are limitless for people with a passion for science and patient wellbeing.
As we enter a post-COVID pandemic world, I would like to think that the life sciences would now top the list of employment sectors for not only STEM graduates but for anyone who is passionate about science and the opportunity to make a difference to people’s lives.
Without question, the pandemic has shone a spotlight on the often-overlooked ability of the biopharmaceutical sector to deliver not only life-changing and life-saving medical advances for individual patients, but to deliver untold social and economic benefits.
A likely flow-on effect of this will be increasing numbers of STEM graduates and professionals in the early stages of their careers seeking employment in this dynamic industry.
The biopharmaceutical sector is already fortunate to attract a large number of STEM graduates, often with majors in chemistry, physics, biochemistry, medical sciences, chemical and biomedical engineering and even maths. For analytic minds, career opportunities in biopharmaceuticals are endless, and I am just one of many, many example of that.
It was not long ago that the worlds of academia and industry were very clearly delineated. These days, those lines are much more blurred and old notions about differences in the ‘quality of science’ have all but gone. Collaborations between the biopharmaceutical industry and academic institutes are commonplace, with the shared goal of addressing unmet medical needs as best and quickly as possible.
One of the greatest differences I have observed in the scientific pursuits of companies and academia is the timelines in which innovations are progressed and accomplished. Drug discovery is being accelerated because we invest so heavily in research and development. In fact, there are now more than 7,800 products in clinical development globally, with nearly 70 per cent of clinical projects focused on potential first-in-class therapies.1
Only through sustained investment in the long and often fraught road to drug discovery has it been possible to increase life expectancy so significantly over the past 30 years.
During my career, I have had the privilege to work on the development and introduction of life-saving and life-improving medicines for medical needs as diverse as infectious diseases and cancer to fertility issues, diabetes and cardiovascular disease.
One of the greatest highlights and honours of my career was leading a team that introduced an entirely new way of treating cancer. We did this resolute that no patient should be left behind. That is what the biopharmaceutical industry is really all about – harnessing scientific and medical innovation for the benefit of people we will most likely never meet.
I have come to realise that, like many of my colleagues and peers, the scientist in me loves being at the forefront of transformational medical innovation. But what really gets people in this sector out of bed every morning is knowing that these advances, and what we do with them, help Australian families live better, healthier and longer lives. Nothing is more rewarding.
A career in biopharmaceuticals comes with the opportunity to help advance medical practice; work closely with doctors; inform, coordinate or undertake clinical research; and have direct access to the earliest clinical data, allowing for important analysis of how it could affect clinical practice.
It also comes with the significant opportunity for progression – regardless of gender, sexuality, colour or creed. The pharmaceutical sector is steadfast in its commitment to remove barriers to diversity, equity and inclusion for the benefit or all. And this is one of the major reasons why I believe life sciences hold such strong prospects for female STEM graduates. As an industry, we are leading the way on gender equity.
My advice to STEM graduates and those early in their science career is to:
A graduate-level role within a biopharmaceutical company can be the first step to a successful and varied career here in Australia and overseas. I am one example of that. Will you be the next?
References: 1. Pharmaceutical Research and Manufacturers of America (PhRMA). Innovation in the Biopharmaceutical Pipeline. December 2021. Available at: https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/G-I/Innovation_in_Biopharmaceuticals.pdf
Josie Downey is Managing Director of Merck Healthcare Australia and New Zealand.